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Abstract
The qualified presumption of safety (QPS) was developed to provide a generic safety evaluation for
biological agents to support EFSA’s Scientific Panels. It is based on an assessment of the taxonomic
identity, the body of knowledge, safety concerns and antimicrobial resistance. Safety concerns identified
for a taxonomic unit (TU) are where possible to be confirmed at strain or product level, reflected by
‘qualifications’. No new information was found that would change the previously recommended QPS TUs
of the 39 microorganisms notified to EFSA between October 2019 and March 2020, 33 were excluded,
including five filamentous fungi, five Escherichia coli, two Enterococcus faecium, two Streptomyces spp.
and 19 TUs already evaluated. Six TUs were evaluated. Akkermansia muciniphila was not recommended
for QPS status due to safety concerns. Clostridium butyricum was not recommended because some
strains contain pathogenicity factors. This TU was excluded for further QPS evaluation. Galdieria
sulphuraria and Pseudomonas chlororaphis were also rejected due to a lack of body of knowledge. The
QPS status of Corynebacterium ammoniagenes (with the qualification ‘for production purposes only’) and
of Komagataella pastoris (with the qualification ‘for enzyme production’) was confirmed. In relation to the
taxonomic revision of the Lactobacillus genus, previously designated Lactobacillus species will be
reassigned to the new species and both the old and new names will be retained in the QPS list.
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Summary
The European Food Safety Authority (EFSA) asked the Panel on Biological Hazards (BIOHAZ) to
deliver a Scientific Opinion on the maintenance of the list of qualified presumption of safety (QPS)
biological agents intentionally added to food or feed. The request included three specific tasks as
mentioned in the Terms of Reference (ToR).
The QPS process was developed to provide a harmonised generic pre-evaluation procedure to
support safety risk assessments of biological agents performed by EFSA’s scientific Panels and Units.
The taxonomic identity, body of knowledge and safety of biological agents are assessed. Safety
concerns identified for a taxonomic unit (TU) are, where possible, to be confirmed at strain or product
level, reflected as ‘qualifications’ that should be assessed at the strain level by the EFSA’s scientific
Panels. A generic qualification for all QPS bacterial TUs applies in relation to the absence of acquired
genes conferring resistance to clinically relevant antimicrobials (EFSA, 2008).
The list of microorganisms is maintained and re-evaluated approximately every 6 months in a
Panel Statement. The Panel Statement also includes the evaluation of microbiological agents newly
notified to EFSA within the 6-month period.
The first ToR requires ongoing updates of the list of biological agents notified to EFSA, in the
context of a technical dossier for safety assessment. The overall list (https://doi.org/10.5281/zenodo.
4498899) was updated with the notifications received since the latest review in October 2019. Within
this period, 39 notifications were received by EFSA, of which 26 were proposed for use as Feed
Additives, two as Food Enzymes, Food Additives and Flavourings, five as Novel Foods, five as Plant
Protection Products and one as a Genetically Modified Organism. The new notifications received
between October 2019 and March 2020 are also included in the current Statement (see Appendix F).
The second ToR concerns the revision of the TUs previously recommended for the QPS list and their
qualifications. For this revision, articles published from July 2019 until December 2019 were assessed.
The articles were retrieved and assessed through an extensive literature search (ELS) protocol
available in Appendix B (see https://doi.org/10.5281/zenodo.3607190) and the search strategies in
Appendix C (see https://doi.org/10.5281/zenodo.3607193). No new information was found that would
affect the QPS status of those TUs and their qualifications.
The third ToR requires a (re)assessment of new TUs notified to EFSA, for their suitability for
inclusion in the updated QPS list at the Knowledge Junction in Zenodo (https://zenodo.org/record/
1146566, Appendix E). The current Statement focuses on the assessments of the TUs that were
notified to EFSA between October 2019 and March 2020. Of the 39 notifications received, 33 were not
included for QPS evaluation. Fourteen of them were excluded from QPS evaluation (five were
notifications of filamentous fungi; five of Escherichia coli, two of Enterococcus faecium, two of
Streptomyces spp.) and 19 were already evaluated.
Six notifications, corresponding to six TUs, were evaluated for possible QPS status; two of these
(Akkermansia muciniphila and Galdieria sulphuraria) for the first time. Clostridium butyricum,
Corynebacterium ammoniagenes, Pseudomonas chlororaphis and Komagataella pastoris were re-
assessed because the recent notifications related to a different intended use or because an update
was requested in relation to the new mandate.
• Akkermansia muciniphila is not recommended for the QPS status due to safety concerns;
• Galdieria sulphuraria is not recommended for the QPS status due to a lack of body of
knowledge regarding its use in the food and feed chain;
• Clostridium butyricum is not recommended for the QPS status because some strains contain
pathogenicity factors; this TU is excluded for further QPS evaluation;
• Pseudomonas chlororaphis is not recommended for the QPS status due to a lack of body of
knowledge;
• The QPS status with the qualification ‘for production purposes only’ of Corynebacterium
ammoniagenes is confirmed;
• The QPS status with the qualification ‘for enzyme production’ of Komagataella pastoris is
confirmed.
The genus Lactobacillus has been recently divided into 25 new genera (Zheng et al., 2020). As a
consequence, the 37 species that are considered as QPS were reclassified into 13 genera. For maintenance
of continuity within the QPS list, all the strains belonging to a previous designed Lactobacillus species will
be transferred to the new species. Both the previous and new names will be retained.
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1. Introduction
The qualified presumption of safety (QPS) approach was developed by the EFSA Scientific
Committee to provide a generic concept for risk assessment within the European Food Safety Authority
(EFSA) for microorganisms intentionally introduced into the food chain, in support of the respective
Scientific Panels and Units in the frame of market authorisations, requiring an EFSA safety assessment
(EFSA, 2007). The list, first established in 2007, has been continuously revised and updated. Each
6 months a Panel Statement is published. These Panel Statements include the results of the
assessment of the relevant new papers related to the TUs with QPS status. They also contain the
assessment of newly arrived TUs to the EFSA Units on Feed, Food Ingredients and Packaging (FIP),
Nutrition, Pesticides and Genetically Modified Organisms (GMO). After 3 years, a QPS opinion is
published summarising the results of the Panel Statements published in that period.
1.1. Background and Terms of Reference as provided by EFSA
A wide variety of microorganisms are intentionally added at different stages into the food and feed
chain. In the context of applications for market authorisation of these biological agents used, either
directly or as sources of food and feed additives, food enzymes and plant protection products, EFSA is
requested to assess their safety.
EFSA work on QPS activities started in 2004 when the Scientific Committee issued a scientific opinion
in continuation of the 2003 working document “On a generic approach to the safety assessment of
microorganisms used in feed/food and feed/food production” prepared by a WG consisting of members of
the former Scientific Committee on Animal Nutrition, the Scientific Committee on Food and the Scientific
Committee on Plants of the European Commission.1 The document, made available for public
consultation, proposed the introduction of the concept of Qualified Presumption of Safety (QPS), to be
applied to selected groups of microorganisms. Microorganisms not considered suitable for QPS status
would remain subject to a full safety assessment. EFSA management asked its Scientific Committee to
consider whether the QPS approach could be applied to the safety assessment of microorganisms across
the various EFSA scientific Panels. In doing so, the Committee was required to take into account the
response of the stakeholders to the QPS approach. In its 2005 opinion (EFSA, 2005), the Scientific
Committee concluded that the QPS approach could provide a generic assessment system that could be
applied to all requests received by EFSA for the safety assessments of microorganisms deliberately
introduced into the food and feed chain. Its introduction was intended to make more transparent and aid
the consistency of approach across the EFSA Panels. Applications involving a taxonomic unit belonging to
a species that falls within a QPS group do not require a full safety assessment.
Several taxonomic units (usually species for bacteria and yeasts, families for viruses) have been
included in the QPS list, either following notifications to EFSA, or proposals made initially by stakeholders
during a public consultation in 2005, even if they were not yet notified to EFSA (EFSA, 2005). The EFSA
Scientific Committee reviewed the range and numbers of microorganisms likely to be the subject of an
EFSA Opinion and, in 2007, published a list of microorganisms recommended for the QPS list.
In their 2007 opinion (EFSA, 2007), the Scientific Committee recommended that a QPS approach
should provide a generic concept to prioritise and to harmonise safety risk assessment of
microorganisms intentionally introduced into the food chain, in support of the respective Scientific
Panels and EFSA Units in the frame of the market authorisations. The same Committee recognised that
there would have to be continuing provision for reviewing and modifying the QPS list and in line with
this recommendation, the EFSA Panel on Biological Hazards (BIOHAZ) took the prime responsibility for
this and started reviewing annually the existing QPS list. In 2008, the first annual QPS update was
published (EFSA, 2008).
In 2014, the BIOHAZ Panel, in consultation with the Scientific Committee, decided to change the
revision procedure; the overall assessment of the taxonomic units previously recommended for the QPS
list (EFSA BIOHAZ Panel, 2013) was no longer carried out annually but over a 3-year period. From 2017,
the search and revision of the possible safety concerns linked to those taxonomic units started instead
to be carried out every 6 months through extensive literature searches (ELS). The update of the 2013
QPS list (EFSA BIOHAZ Panel, 2013) was done in 2016 (EFSA BIOHAZ Panel, 2017). From 2016 on, the
QPS list (https://zenodo.org/record/1146566) and the list of notifications to EFSA (https://zenodo.org/
record/3607183) are constantly updated, independent of the QPS opinion and available at the
Knowledge Junction in Zenodo. The most recent QPS opinion (EFSA BIOHAZ Panel, 2020b summarises
1 https://ec.europa.eu/food/sites/food/files/safety/docs/sci-com_scf_out178_en.pdf
BIOHAZ statement on QPS: suitability of taxonomic units notified until March 2020
www.efsa.europa.eu/efsajournal 6 EFSA Journal 2020;18(7):6174
the main results of the 3-year ELS on the QPS TUs, together with an update of the process for granting
QPS Status. In the meantime, every 6 months a Panel Statement, compiling the assessments for a QPS
status of the microbiological agents notified to EFSA requested by the Feed Unit, the Food Ingredients
and Packaging (FIP) Unit, the Nutrition Unit, the Pesticides Unit and the Genetically Modified Organisms
(GMO) Unit, as well as the summary of each 6-month ELS exercise, has been produced and published.
Each QPS Panel Statement contains the evaluations of the new notifications for microorganisms
submitted for possible QPS status. It also contains the result of an Extensive Literature Search (ELS)
performed every 6 months concerning possible new safety concerns related to the TUs already included
in the QPS list. The data identified are used to decide whether any TU may or may not remain in the
QPS list, and whether any qualifications need to be revised.
Establishing a QPS status is based on four pillars: the taxonomic grouping for which QPS is sought
(“taxonomic identification”); whether sufficient information is available about the proposed group of
organisms to conclude on human/animal exposure by food/ feed (“body of knowledge”); whether the
grouping proposed contains known pathogens (“safety”) and, finally, the intended end use (“intended
use”). If a hazard related to a TU is identified, which can be tested at the strain or product level, a
‘qualification’ to exclude that hazard may be established. The subject of these qualifications for the
microbial strain under investigation is evaluated by the EFSA Unit to which the application dossier has
been allocated. Absence of acquired genes coding for resistance to antimicrobials relevant for humans
and animals is a generic qualification for all bacterial TUs; the absence of antimycotic resistance should
be proved if the yeasts are to be used as viable organisms in the food or feed chains. The qualification
‘for production purpose only’ implies the absence of viable cells of the production organism in the final
product and can also be applied to food and feed products based on microbial biomass (EFSA BIOHAZ
Panel, 2020a,b).
Because the QPS evaluation is, after its initial creation only triggered through an application dossier
notified to EFSA, the QPS list is not exhaustive.
In summary, the QPS provides a generic safety pre-assessment approach for use within EFSA that
covers safety concerns for human, animals and the environment. In the QPS concept, a safety
assessment of a defined taxonomic unit is performed independently of the legal framework under
which the application is made in the course of an authorisation process. Although general human
safety is part of the evaluation, specific issues connected to type and level of exposure of users
handling the product (e.g. dermal contact, inhalation, ingestion) are not addressed. In the case of
Genetically Modified Microorganisms (GMM) for which the species of the recipient strain qualifies for
the QPS status, and for which the genetically modified state does not give rise to safety concerns, the
QPS approach can be extended to genetically modified production strains (EFSA BIOHAZ Panel, 2018).
The assessment of potential allergenicity to microbial residual components is beyond the QPS remit;
however, if there is science-based evidence for some microbial species it is reported. These aspects are
separately assessed, where applicable, by the EFSA Panel responsible for assessing the application.
The lowest TU for which the QPS status is granted is the species level for bacteria, yeasts and
protists/algae, and family for viruses.
Filamentous fungi, bacteriophages, Streptomycetes, Oomycetes, Enterococcus faecium and
Escherichia coli are excluded from the QPS assessments based on an ambiguous taxonomic position or
the possession of potentially harmful traits.
The Terms of Reference are as follows:
ToR 1: Keep updated the list of biological agents being notified in the context of a technical dossier
to EFSA Units such as Feed, Pesticides, Food Ingredients and Packaging (FIP) and Nutrition, for
intentional use directly or as sources of food and feed additives, food enzymes and plant protection
products for safety assessment.
ToR 2: Review taxonomic units previously recommended for the QPS list and their qualifications
when new information has become available. The latter is based on a review of the updated literature
aiming at verifying if any new safety concern has arisen that could require the removal of the
taxonomic unit from the list, and to verify if the qualifications still efficiently exclude safety concerns.
ToR 3: (Re) assess the suitability of new taxonomic units notified to EFSA for their inclusion in the
QPS list. These microbiological agents are notified to EFSA and requested by the Feed Unit, the FIP
Unit, the Nutrition Unit or by the Pesticides Unit.
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2. Data and methodologies
2.1. Data
In reply to ToR 2, concerning the revision of the TUs previously recommended for the QPS list and
their qualifications, an extensive literature search (ELS) was conducted as described in Appendix B –
ELS protocol, see https://doi.org/10.5281/zenodo.3607190, and in Appendix C Search strategies – see
https://doi.org/10.5281/zenodo.3607193, respectively.
In reply to ToR 3, (re)assessment of the suitability of TUs notified within the time period covered by
this Statement (from October 2019 to March 2020) is carried out. The literature review considered the
identification, the body of knowledge, the potential safety concerns and the knowledge on acquired
antimicrobial resistance (AMR). Relevant databases, such as PubMed, Web of Science, CAB Abstracts
or Food Science Technology Abstracts (FSTA) and Scopus, were searched. More details on the search
strategy, search keys and approach are described in Appendix A.
Only valid TUs covered by the relevant international committees on the nomenclature for
microorganisms are considered for the QPS assessment.
The taxonomy of the genus Lactobacillus has recently been revised (Zheng et al., 2020). The
consequences for the QPS assessment and the QPS list are addressed in this Statement (see
Section 3.4).
2.2. Methodologies
2.2.1. Evaluation of a QPS recommendation for taxonomic units notified to EFSA
In response to ToR 1, the EFSA Units were asked to update the list of biological agents being
notified to EFSA. A total of 39 notifications were received between October 2019 and March 2020, of
which 26 were for feed additives, 2 for food enzymes and food additives, 5 for novel foods, 5 for plant
protection products and 1 for a genetically modified organism (Table 1).
In response to ToR 3, of the 39 notifications received, 33 were not included for QPS evaluation.
Fourteen of them were excluded from QPS evaluation (five were notifications of filamentous fungi; five
of Escherichia coli, two of Enterococcus faecium, two of Streptomyces spp.) and 19 were already
evaluated.
Six notifications, corresponding to six TUs, were evaluated for possible QPS status, two of these
(Akkermansia muciniphila and Galdieria sulphuraria) for the first time. Clostridium butyricum,
Corynebacterium ammoniagenes, Pseudomonas chlororaphis and Komagataella pastoris were re-
assessed because the recent notifications intended a different use or because an update was
requested in relation to the new mandate.
Table 1: Notifications received by EFSA, per risk assessment area and by biological group, from
October 2019 to March 2020
Risk assessment area
Not evaluated in this








Feed additives 16 8 2 26
Bacteria 14 7 2 23
Filamentous fungi 0 1 0 1
Yeasts 2 0 0 2
Novel foods 0 3 2 5
Bacteria 0 2 1 3
Filamentous fungi 0 1 0 1
Protists/Algae 0 0 1 1
Yeasts 0 0 0 0
Plant protection products 2 2 1 5
Bacteria 2 0 1 3
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2.2.2. Evaluating the use of Artificial Intelligence in the context of
Bifidobacterium, Lactobacillus and Lactococcus
To explore the potential application of Artificial Intelligence (AI) for screening papers in the context
of the QPS project, the performances of that technique were assessed against the previous batch of
papers retrieved for the Bifidobacterium, Lactobacillus and Lactococcus taxonomic units.
To that purpose, the DistillerAI Toolkit included in the DistillerSR online software was used.
DistillerAI ‘Preview and Rank’ function was used mapping the papers from ‘Title screening’ to
‘Article evaluation’. The SVM algorithm with 100% training set and 100% references to preview was
used and the references were subsequently tagged. The algorithm was trained on the combined
results of the two reviewers in the QPS rounds from 1 June 2016 to 31 December 2018. This is
considered a conservative approach since, in the case of conflicts among the experts, the algorithm
considers the paper as relevant.
The AI predicted screening results on the batch of papers corresponding to the period January–
June 2019 were obtained and compared with the results obtained by the two reviewers in the real
exercise.
The results of the exercise showed that:
• for Bifidobacterium, from a total number of 270 references in the batch, DistillerAI missed four
papers that were considered as relevant by the experts at the end of the Title and Abstract
step. These four papers were not considered relevant for QPS by the experts at the stage of
Article evaluation.
• for Lactobacillus, from a total number of 620 references in the batch, DistillerAI missed four
papers that were considered as relevant by the experts at the end of the Title and Abstract
step. At the stage of Article evaluation, the experts did not consider relevant for QPS two of
these four papers, while for the other two it was concluded that there was no information that
could potentially lead to a change in the QPS status of the TU.
• for Lactococcus, from a total number of 165 references in the batch, DistillerAI did not miss
any paper that was considered as relevant by the experts at the end of the Title and Abstract
step.
Hence, the AI function did not miss any relevant paper for the three TUs considered.
On the basis of these results, it was decided to use the AI function in parallel with a human
reviewer to screen the current batch of papers for these three TUs.
The results of the exercise showed that:
Risk assessment area
Not evaluated in this








Filamentous fungi 0 2 0 2
Viruses 0 0 0 0
Food enzymes, food additives and
flavourings
1 1 0 2
Bacteria 0 0 0 0
Filamentous fungi 0 1 0 1
Yeasts 1 0 0 1
Genetically modified organism 0 0 1 1
Yeasts (1) 0 1 1
Total 19 14 6 39
QPS: qualified presumption of safety.
(a): The number includes five notifications of filamentous fungi, two of Enterococcus faecium (bacterium), five of Escherichia coli
(bacterium) and two of Streptomyces spp., all excluded from QPS evaluation.
(b): Six notifications corresponding to six TUs, one was last evaluated in 2015 (Pseudomonas chlororaphis), another one in 2014
(Clostridium butyricum), two already have a QPS with qualifications but were now notified for another purpose
(Corynebacterium ammoniagenes, Komagataella pastoris) and two were evaluated for the first time (Akkermansia
muciniphila, Galdieria sulphuraria).
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• for Bifidobacterium, from a total number of 253 references in the batch, DistillerAI missed one
paper that was considered as relevant by the expert at the end of the Title and Abstract step.
At the stage of Article evaluation, this paper was not considered as pertaining to the
Bifidobacterium TU by the Experts.
• for Lactobacillus, from a total number of 661 references in the batch, DistillerAI missed two
papers that were considered as relevant by one of the experts at the end of the Title and
Abstract step. At the stage of Article evaluation, one of the experts judged one paper as ‘not
dealing with safety concerns’ while the other one was assessed as ‘not bringing information
that could potentially lead to a change to the QPS status’, since the microorganism was used
as probiotics which do not fall under the remit of the QPS assessment.
• for Lactococcus, from a total number of 150 references in the batch, DistillerAI missed one
paper that was considered as relevant by the experts at the end of the Title and Abstract step.
At the stage of Article evaluation, this paper was assessed as ‘not dealing with safety concerns’
by the experts.
The use of AI resulted in a large number of potentially relevant papers at the end of the screening
phase. On the other hand, the algorithm did not miss any paper identified as relevant by the human
reviewers in the final assessment.
2.2.3. Use of Artificial Intelligence in the context of the yeast and Bacillus
taxonomic units
The AI function alone was used for pre-screening of the large number of papers for the yeast and
Bacillus taxonomic units, followed by a second screening by two experts of the articles retrieved by AI.
2.2.4. Monitoring of new safety concerns related to species with QPS status
The aim of the ELS carried out in response to ToR 2 (review of the recommendations for the QPS
list and specific qualifications) was to identify any publicly available studies reporting on safety
concerns for humans, animals or the environment caused by QPS organisms since the previous QPS
review (i.e. publications from July to December 2019).
For case reports of human infections or intoxications, additional important information is whether
any negative impacts are confined to affected persons with conditions favouring opportunistic
infections, e.g. immunosuppression, and whether transmission occurred through food or other routes
(e.g. medical devices). Studies indicating the presence of virulence factors (e.g. toxins and enzymes
that may contribute to the pathogenicity of the microorganism) in the TU are also reported as relevant
for the identification of potential safety concerns.
Several of the QPS-TUs are sporadically reported as causing infections in individuals with recognised
predisposing conditions for the acquisition of opportunistic infections e.g. cardiovascular conditions
favouring endocarditis, people in the extreme lower or upper age spectrum or other conditions which
can lead to impairment of the immunological system, such as patients submitted to transplants,
undergoing cancer therapy, with physical trauma or tissue damage or HIV patients. Moreover,
gastrointestinal tract-related conditions with mucosal impairment can also be predisposing factors for
infections. Previous use of the microorganisms as food supplements for humans was reported in many
of these cases. The living microorganism used as a food supplement does not fall under the remit of
the QPS assessment. Nevertheless, QPS assessment takes into consideration these reports, extracting
relevant information whenever justified. For a detailed protocol of the process and search strategies,
refer to Appendices B and C.
After removal of duplicates, 2,557 records were submitted to the title screening step, which led to
the exclusion of 2,327 of them. The remaining 230 records were found eligible for the Title and
abstract screening step, which led to the exclusion of 83 of these. Of the 147 articles that finally
reached the Article evaluation step (full text), 37 were considered to be relevant for the QPS project
and were further analysed.
The flow of records from their identification by the different search strategies (as reported in
Appendix C) to their consideration as potentially relevant papers for QPS is shown in Table 2.
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3. Assessment
The search strategy (key words, literature databases, number of papers found) followed for the
assessment of the suitability of TUs notified to EFSA for their inclusion in the updated QPS list (reply to
ToR 3) can be found in Appendix A.
3.1. Taxonomic units evaluated during the previous QPS mandate and
re-evaluated in the current Statement
3.1.1. Bacteria
3.1.1.1. Clostridium butyricum
A new evaluation of Clostridium butyricum was made because an update was requested in relation
to the new QPS mandate. C. butyricum was considered as unsuitable for QPS in 2008, 2011 and 2014
assessments because some strains can produce botulinum toxin E (EFSA, 2008; EFSA BIOHAZ Panel,
2011, 2014).
Identity
Clostridium butyricum is a valid taxonomic species with standing in nomenclature. It is a Gram-
positive, sporulating, strictly anaerobic bacterium, able to produce butyric acid.














Number of articles retrieved
Bacteria (total) 2,159 156 100 7
Bacillus 443 11 6 3
Bifidobacterium/
Carnobacterium divergens
253 65 48 1
Corynebacterium
glutamicum




247 3 0 0
Lactobacilli 661 39 33 3
Lactococcus lactis 150 13 10 0
Leuconostoc/
Microbacterium imperiale
65 8 2 0
Oenococcus/Pasteuria
nishizawae
35 0 0 0
Pediococci 178 9 0 0
Propionibacterium 25 0 0 0
Streptococcus
thermophilus
55 7 1 0
Viruses (total) 106 4 1 0
Alphaflexiviridae 42 2 0 0
Baculoviridae 64 2 1 0
Yeasts 292 70 46 29
Total 2,557 230 147 36
Excluded 2,327 83 111
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Body of knowledge
C. butyricum occurs in a variety of environments and is a common human and animal gut
commensal bacterium. In recent years, several papers describing the beneficial effects of some strains
of C. butyricum as probiotics in animals and humans have been published (Cassir et al., 2016) and a
single strain has been assessed by EFSA as a feed additive (EFSA BIOHAZ Panel, 2014). This species
has also been studied for use in biotechnological processes, such as dechlorination of trichloroethene
(Lo et al., 2020), as well as the production of hydrogen (Ortigueira et al., 2019) and butyrate (Detman
et al., 2019).
Safety concerns
Some strains of C. butyricum are able to form botulinum neurotoxin type E (BoNT/E) (Hauser et al.,
1992; Peck, 2009). Toxigenic strains of this species are responsible for infant botulism (Fenicia et al.,
1999; Abe et al., 2008) and can be involved in food-borne intoxications. The gene coding for botulinum
neurotoxin type E was detected only in a minority of C. butyricum strains (Hauser et al., 1992). The
genetic locus coding for BoNT/E is generally harboured by megaplasmids (bigger than 500 Kb) as also
confirmed by WGS (Halpin et al., 2017). C. butyricum has been identified as an aetiological cause of
necrotising enterocolitis in preterm neonates (Cassir et al., 2016; Sch€onherr-Hellec et al., 2018; Hosny
et al., 2019a,b) and in adults (Sato et al., 2018). The strains isolated from necrotising enterocolitis
harbour four genes encoding polypeptides similar to haemolysins (Cassir et al., 2016). An additional
concern is indicated by one report of bacteraemia in a drug addict who very likely injected himself with a
drug contaminated with C. butyricum (Gardner et al., 2008). Occasionally, an enterotoxin-producing
C. butyricum was associated with antibiotic-associated diarrhoea (Kwok et al., 2014).
Antimicrobial resistance aspects
Acquired resistance to beta-lactams (due to b-lactamase production), tetracyclines (tet genes),
macrolides (erm genes) and clindamycin (lmrB) has been reported (Ferraris et al., 2010).
Conclusions on a recommendation for the QPS list
The information collected reveals that some strains can harbour pathogenicity factors. Therefore,
C. butyricum is not recommended for the QPS list, confirming the previous conclusion on this species
attained in 2008, 2011 and 2014.
Since the inappropriateness of granting a safety status to the species C. butyricum has been
recognised in several EFSA Opinions (EFSA, 2008; EFSA BIOHAZ Panel, 2011, 2014), the Panel confirms
the exclusion of this species from future QPS evaluations.
3.1.1.2. Corynebacterium ammoniagenes
A new evaluation of Corynebacterium ammoniagenes was made following its notification as a
sensory additive in feed. It was recently evaluated (EFSA BIOHAZ Panel, 2019) and included in the
QPS list with the qualification ‘for production purposes only’.
Identity
C. ammoniagenes is a species with standing in nomenclature. It is a Gram-positive, non-spore
forming, non-motile, rod-shaped, facultatively anaerobic bacterium.
Body of knowledge
It is widely used for the industrial production of nucleotides, and its use as single-cell protein diets
in shrimp, pigs and chicken has been reported (Wang et al., 2013; An et al., 2018; Hamidoghli et al.,
2018), without any negative effects on blood, bone characteristics or meat quality (An et al., 2018).
Additionally, the use of this TU for riboflavin synthesis was reported (Koizumi et al., 2000). It has
recently been used for the production of riboflavin and related cofactors using whole-cell biocatalytic
processes (Liu et al., 2020).
No information about the use of viable cells in food or feed was found in the scientific literature.
Safety concerns
No additional information was found in relation to the pathogenicity of the organism.
Antimicrobial resistance aspects
No additional information was found in relation to antimicrobial resistance.
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Conclusions on a recommendation for the QPS list
The QPS status of C. ammoniagenes is confirmed with the qualification ‘for production purposes
only’.
3.1.1.3. Pseudomonas chlororaphis
A new evaluation of Pseudomonas chlororaphis was made because an update was requested in
relation to the new QPS mandate. P. chlororaphis was considered as unsuitable for QPS in 2009 and
2013 (EFSA BIOHAZ Panel, 2009, 2013)
Identity
Pseudomonas chlororaphis is a valid species name with standing in nomenclature (Johnson and
Palleroni, 1989). It is a Gram-negative strictly aerobic flagellated rod. The species contains four
subspecies P. clororaphis subsp. chlororaphis, subsp. aureofaciens, subsp. aurantiaca (Peix et al., 2007)
and subsp. piscium (Burr et al., 2010). P. chlororaphis strains have been isolated from the wider
environment but also in association with plants and fish intestines. It is closely related to P. protegens
which was also isolated from the plant rhizosphere (Ramette et al., 2011).
Body of knowledge
P. chlororaphis is typically an aerobic heterotroph, but has also been shown to perform
denitrification within the rhizosphere, thus having biogeochemical significance in terms of producing
dinitrogen gas from nitrate (Palleroni, 2005). It is mesophilic with an ideal growth temperature range
between 20°C and 28°C and grows best around a pH of 6.3–7.5 (EFSA BIOHAZ Panel, 2015).
P. chlororaphis strains are used as biocontrol agents due to their complex interactions with plant
metabolism (Ciancio et al., 2016). Strains are described to produce molecules with antifungal activity
such as phenazines (Mercado-Blanco and Bakker, 2007), with antibacterial activity (Dorosky et al.,
2018) and with insecticidal activity (Anderson et al., 2018). Also, the ability to colonise the plant and
stimulate the root system, increasing nutrient uptake, has been reported; a feature linked to the
biosynthetic gene cluster for indole-3-acetic acid metabolism (Flury et al., 2016). P. chlororaphis has
also been used in industrial acrylamide production, producing nitrile hydrases that hydrate nitriles to
amides (Yamada and Kobayashi, 1996).
Comparative genome analysis indicates the absence of genes coding for plant virulence factors such
as those located in the genome islands PAPI-1 and PAPI-2, the presences of genes required for the
biosynthesis of phytotoxins (syringomycin, syringopeptine, coronatine) and exoenzymes (cellulases,
pectinases and pectin lyases) involved in the degradation of plant cell walls (EFSA BIOHAZ Panel, 2015).
Safety concerns
P. chlororaphis has only rarely been reported as a cause of human infection. Monta~na et al. (2018)
recovered a P. chlororaphis strain resistant to several beta-lactam antibiotics from a respiratory tract and
anal mucous sample from a 63-year-old man suffering from aspirate pneumonia and being HIV positive.
A metallo-beta-lactamase-producing P. chlororaphis was also reported from a blood culture of a
59-year-old male who suffered from a prolonged febrile syndrome and was suspected of having
endocarditis (Faccone et al., 2014). The strain was identified based on partial 16S rDNA gene
sequence analysis (803 bp), leaving some doubts about its identity.
Antimicrobial resistance aspects
No relevant further information was found in relation to antimicrobial resistance.
Conclusions on a recommendation for the QPS list
P. clororaphis is not recommended for the QPS list due to a lack of body of knowledge.
3.1.2. Yeasts
3.1.2.1. Komagataella pastoris
A new evaluation of Komagataella pastoris was made following its notification as a sensory additive.
The anamorph of K. pastoris is not described. It was recently evaluated (EFSA BIOHAZ Panel, 2020a,b)
and included in the QPS list. The previous name of this species was Pichia pastoris.
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Identity
K. pastoris is a species with standing in nomenclature.
Body of knowledge
A search with Komagataella pastoris and Pichia pastoris was conducted including the last 10 years.
None of the articles referred to the use of this TU as viable cells or uses other than enzyme
production.
Safety concerns
No additional information was found in relation to pathogenicity of the organism.
Antimicrobial resistance aspects
No additional information was found in relation to antimicrobial resistance.
Conclusions on a recommendation for the QPS list
No references reporting possible concerns for human or animal safety, or other related aspects were
identified. Therefore, the QPS status does not change. The qualification is unchanged, QPS only applies
when the species is used for enzyme production because of a lack of knowledge for other uses.




Akkermansia muciniphila is a valid species with standing in nomenclature. It belongs to the Phylum
Verrucomicrobia (Oren and Garrity, 2017). The type strain is MucT (Derrien et al., 2004). Its GC-content
is 55.8%, as determined through whole genome sequencing (Hahnke et al., 2016). A. muciniphila is a
Gram-negative, strictly anaerobic, non-motile bacterium that grows optimally in media with mucin but
that can also be propagated on a limited number of sugars. The genomes of 23 Akkermansia spp. strains
(Xing et al., 2019) and of 39 strains of A. muciniphila (Guo et al., 2017) were compared and revealed
phylogenetic and phenotypical relationships, suggesting that Akkermansia is a monophyletic genus.
Body of knowledge
A. muciniphila is abundant in the colon of humans and animals but has also been detected in
human milk samples (Collado et al., 2007; Geerlings et al., 2018). It has been associated with health
promotion (Gomez-Gallego et al., 2016; Derrien et al., 2017) because its prevalence appears to be
decreased in gut microbiota samples of people suffering from the ‘metabolic syndrome’, which includes
obesity, diabetes, cardiometabolic disease and low-grade inflammation. In addition, A. muciniphila is
postulated to increase the efficacy of cancer immunotherapy and to ameliorate the symptoms of
alcohol-related liver disease (Grander et al., 2018; Zheng et al., 2019). These data prompted research
aiming to the use of A. muciniphila as a probiotic organism (Gomez-Gallego et al., 2016; Zhang et al.,
2019).
Safety concerns
Depommier et al. (2019) performed a human volunteer study with a daily oral administration of
1010 A. muciniphila, either alive or pasteurised, to 32 overweight/obese insulin-resistant volunteers for
3 months. The administration was demonstrated to be safe and well tolerated for both live and
pasteurised cells, while a decrease in total plasma cholesterol and insulinaemia was observed. This
study confirmed the results of a previous study of administration for 2 weeks of live and pasteurised A.
muciniphila to humans (Plovier and Cani, 2017) and a collection of other reports on safety upon
dispensation to rodents (see Gomez-Gallego et al., 2016, for a comprehensive review). However, A.
muciniphila might contribute to progression of neural diseases, possibly through its ability to degrade
mucin, which would induce local inflammation, increase of gut permeability, loss of mucosal integrity
(Radisavljevic et al., 2018) and, eventually, endotoxaemia. The prevalence of A. muciniphila has been
found to be increased in Parkinson’s disease (Hill-Burns et al., 2017; Heintz-Buschart et al., 2018),
multiple sclerosis (Berer et al., 2017; Cekanaviciute et al., 2017), Alzheimer’s disease (Vogt et al.,
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2017; Zhuang et al., 2018) and autism spectrum disorders (Finegold et al., 2010; De Angelis et al.,
2013), although for autism, depletion of the microorganism was reported as well (Wang et al., 2011).
Antimicrobial resistance aspects
Whole genome analysis of 39 A. muciniphila strains revealed the presence of several antimicrobial
resistance genes (sul2 for sulfonamides and aph(6)-Id and aph(3”)-Ib for aminoglycosides resistance)
(Guo et al., 2017).
Conclusions on a recommendation for the QPS list




Galdieria sulphuraria is a mixotrophic, unicellular, red microalgae (Graziani et al., 2013) from the
Cyanidiophyceae class, order Cyanidiales, family Galdieriaceae, genus Galdieri.2 It is a valid taxonomic
species.
Body of knowledge
G. sulphuraria has so far only been isolated from volcanic soils; it is thermotolerant (up to 56°C),
acidophilic (down to pH 0), and is more resistant to salt, arsenic and toxic metals than most other
microorganisms. Its genome harbours up to 5% of genes most likely acquired through horizontal gene
transfer, probably contributing to its adaptation to extreme habitats (Rossoni et al., 2019). Its use has
been explored for different biotechnological applications: e.g. for production of energy (Cheng et al.,
2019), bioactive food ingredients (thermotolerant phycocyanin and phytochemicals, Eriksen, 2008;
Sorensen et al., 2013; Sloth et al., 2017; Massa et al., 2019; Rahman et al., 2019), carotenoids
(Graziani et al., 2013), highly branched glycogen (Martinez-Garcia et al., 2017) and for wastewater
treatment (Selvaratnam et al., 2014; Henkanatte-Gedera et al., 2015; Ju et al., 2016; Cheng et al.,
2020). Besides cultivation in bioreactors, also cultivation in open pond systems, wastewater and waste
streams from the food industry have been explored (Hirooka and Miyagishima, 2016; Sloth et al.,
2017; Massa et al., 2019). Information on human exposure is limited.
The body of knowledge concerns mainly the description of the characteristics of the strains, the
genetic basis of their adaptation to extreme conditions and their potential in biotechnological applications.
Modeste et al. (2019) performed a safety study of the dried biomass of a particular strain, using an Ames
bacterial reverse mutation test, an in vitro mammalian cell micronucleus test and an oral toxicity study in
rats. No toxicity was observed and the no observed adverse effect level (NOAEL) was established as 5,000
mg/kg per day.
Safety concerns
No reports in relation to safety concerns were found
Antimicrobial resistance aspects
Not applicable
Conclusions on a recommendation for the QPS list
G. sulphuraria is not recommended for the QPS status due to a lack of body of knowledge
regarding its use in the food or feed chain.
3.3. Monitoring of new safety concerns related to organisms on the QPS
list
The summaries of the evaluation of the possible safety concerns for humans, animals or the
environment described and published since the previous ELS exercise (i.e. articles published between
July and December 2019, as described in Appendices B and C) with reference to the articles selected
as potentially relevant for the QPS exercise (Appendix D) for each of the TUs or groups of TUs that are
part of the QPS list (Appendix E), are presented below.
2 https://www.gbif.org
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3.3.1. Gram-positive non-sporulating bacteria
3.3.1.1. Bifidobacterium spp.
A search for papers potentially relevant for the QPS evaluation of Bifidobacterium species and
Carnobacterium divergens3 provided 253 references. The analysis of their titles left 65 articles; the rest
were discarded because they did not deal with safety concerns. Forty-eight articles were found
relevant for the QPS evaluation of Bifidobacterium spp. at the level of title and abstract screening.
Forty-seven of these articles were not in English or not dealing with safety concerns. One article was
considered for further evaluation (Pruccoli et al., 2019). The paper described a case of bacteraemia in
a 5-month child with a diagnosis of heart disease. Although the composition of the probiotics that the
child received was checked and revealed the presence of Bifidobacterium longum, the bacterial
isolation from the patients referred only to a positive blood culture for Bifidobacterium spp. without
further identification and specifications.
Based on the available evidence as described above, the QPS status of Bifidobacterium spp. is not
changed.
Carnobacterium divergens
A search for papers potentially relevant for the QPS evaluation of QPS Bifidobacterium species and
Carnobacterium divergens13 provided 253 references. The analysis of their titles left 65 articles; the
rest were discarded because they did not deal with safety concerns. No article was considered relevant
at the level of title and abstract screening for this TU. Consequently, the QPS status of C. divergens is
not changed.
3.3.1.2. Corynebacterium glutamicum
A search for papers potentially relevant for the QPS evaluation of Corynebacterium glutamicum
provided 47 references. One paper reached the level of title and abstract screening but did not reach
full text evaluation. Therefore, no new safety concerns were identified and the QPS status of
C. glutamicum is not changed.
3.3.1.3. Lactobacillus spp.
The search for papers on the 37 Lactobacillus spp. included in the QPS list that might raise safety
concerns provided a total of 661 references. Title screening left 39 references for abstract inspection,
which reduced their number to 33. Full paper review allowed the recognition of three articles dealing
with safety concerns. Two of them dealt with L. rhamnosus infections linked to probiotic consumption
(Cavicchiolo et al., 2019; Yelin et al., 2019) while the third described a prosthetic aortic valve
endocarditis that was associated with L. paracasei in a patient with no history of probiotic intake (Ajam
et al., 2019). The ascription of this last case is doubtful; the organism was isolated from blood and
identified ‘by culture’ with no further specification. Moreover, culture implies phenotypical identification,
which is known not to be reliable for lactobacilli. All three papers dealt with infections that occurred in
patients with underlying illnesses that probably compromised their immunological responses. The case
described in the paper by Ajam et al. (2019) was a 75-year-old woman suffering from the Birt–Hogg–
Dube syndrome, which is associated with skin and kidney tumours and lung cysts development that
predispose for pneumothorax. In addition, she had suffered an aortic stenosis 9 years previously that
needed to be replaced by the prosthetic valve that became colonised. The paper from Cavicchiolo
et al. (2019) describes bacteraemia in three premature babies due to L. rhamnosus. One of them, a
girl born at 31 weeks gestation and weighing 770 g at birth, had been fed with a probiotic supplement
from her third day onwards. The two other affected patients were two boys, admitted to the same
open intensive care unit, but not having received the probiotic supplement (no details on these two
boys are provided, other than stating that all three were presented with central catheters). All of them
developed bacteraemia due to a L. rhamnosus strain that was indistinguishable from the lactobacilli in
the probiotic supplement. Finally, Yelin et al. (2019) presented a retrospective study relating probiotic
use with Lactobacillus infection in ICU patients, having found that about 1% of these developed
bacteraemia by a Lactobacillus strain that was identical to that included in the probiotic preparation
based on WGS comparison.
Case reports related to the administration of living microorganisms used as probiotics are reported
but do not fall under the remit of the QPS assessment, as explained in Section 2.2.4.
3 These two TUs were searched together for practical reasons.
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The ELS did not identify any information that would change the status of the Lactobacillus species
included in the QPS list.
3.3.1.4. Lactococcus lactis
A search for papers potentially relevant for the QPS evaluation of Lactococcus lactis provided 150
references. Thirteen papers qualified for screening at the title/abstract level. Three were discarded and
the remaining 10 papers were assessed as full texts. None of them dealt with safety concerns.
Based on the available evidence as described above, the QPS status of Lactococcus lactis is not
changed.
3.3.1.5. Leuconostoc spp.
A search for papers potentially relevant for the QPS evaluation of QPS Leuconostoc species and
Microbacterium imperiale14 provided 65 references. The analysis of their title/abstracts left eight
articles; six were discarded because they did not deal with safety concerns. Two articles reached full
text evaluation, but one was dealing with another TU and the other was not available in English.
Consequently, the QPS status of Leuconostoc spp. is not changed.
3.3.1.6. Microbacterium imperiale
A search for papers potentially relevant for the QPS evaluation of QPS Leuconostoc species and
Microbacterium imperiale14 provided 65 references. The analysis of their title/abstracts left eight
articles; six were discarded because they did not deal with safety concerns. No article was considered
relevant for this TU. Consequently, the QPS status of M. imperiale is not changed.
3.3.1.7. Oenococcus oeni
A search for papers potentially relevant for the QPS evaluation of Oenococcus oeni and Pasteuria
nishizawae14 (see Section 3.3.2.3) provided 35 references. The analysis of their title/abstracts left no
article for consideration. Consequently, the QPS status of O. oeni is not changed.
3.3.1.8. Pediococcus spp.
A search for papers potentially relevant for the QPS evaluation of Pediococcus spp. provided
178 references. The analysis of their title/abstracts left nine articles for the evaluation phase which
were not related to this TU or not dealing with safety concerns. No article reached the full text
evaluation stage. Consequently, the QPS status of Pediococcus spp. is not changed.
3.3.1.9. Propionibacterium
A search for papers potentially relevant for the QPS evaluation of Propionibacterium spp. provided
25 references. Following the analysis of their title/abstracts, no articles were selected for the full article
evaluation phase; thus, no new safety concerns were identified. Consequently, the QPS status of
Propionibacterium spp. is not changed.
3.3.1.10. Streptococcus thermophilus
A search for papers potentially relevant for the QPS evaluation of Streptococcus thermophilus
provided 55 references. The analysis of their titles left seven articles for title and abstract screening.
One reached the evaluation phase but was not dealing with safety concerns. Therefore, the QPS status
of S. thermophilus is not changed.
3.3.2. Gram-positive spore-forming bacteria
3.3.2.1. Bacillus spp.
A search for papers potentially relevant for Bacillus spp. and Geobacillus stearothermophilus
provided 924 references. The AI analysis left 443 articles. The analysis of their titles by two experts
left 11 articles for the title/abstracts phase, and from these six articles passed to the full text phase for
further analysis. For one reference, no full paper was retrieved, and two papers did not deal with
safety concerns. Three papers had serious methodological problems in relation to strain identification
and source attribution and were not food related (Al-Tulaibawi, 2019; Nadaș et al., 2019; Thanganadar
Appapalam et al., 2019). Al-Tulaibawi (2019) described the isolation of B. subtilis from a urinary tract
infection of diabetic patients; Thanganadar Appapalam et al. (2019) the isolation of B. subtilis from
diabetic foot ulcers; Nadaș et al. (2019) the isolation of B. pumilus from dogs with conjunctivitis.
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The ELS did not come up with any information that would change the status of the Bacillus species
included in the QPS list and confirmed the qualification ‘absence of cytotoxicity’.
3.3.2.2. Geobacillus stearothermophilus
A search for papers potentially relevant Bacillus spp. and Geobacillus stearothermophilus14 provided
924 references. The AI analysis left 443 articles. The analysis of their titles by two experts left 11
articles, for six of which the full texts were analysed. None dealt with this species. Consequently, the
QPS status G. stearothermophilus is not changed.
3.3.2.3. Pasteuria nishizawae
A search for papers potentially relevant for the QPS evaluation of Oenococcus oeni and Pasteuria
nishizawae14 provided 35 references. The analysis of their title/abstracts left no article for
consideration. Consequently, the QPS status of P. nishizawae is not changed.
3.3.3. Gram-negative bacteria
3.3.3.1. Gluconobacter oxydans
A search for papers potentially relevant for the QPS evaluation of Gluconobacter oxidans and
Xanthomonas campestris14 provided 247 references. The analysis of their titles left three articles,
which were discarded following the title and abstract screening. No paper reached the final selection
phase for this TU. Consequently, the QPS status of G. oxydans is not changed.
3.3.3.2. Xanthomonas campestris
A search for papers potentially relevant for the QPS evaluation of Gluconobacter oxidans and
Xanthomonas campestris14 provided 247 references.
The analysis of their titles left three articles which were discarded in the title and abstract
screening.
The analysis of their titles left one article. No paper reached the evaluation phase for this TU.
Consequently, the QPS status of X. campestris is not changed.
3.3.4. Yeasts
The ELS searches for potentially relevant studies on the yeasts with QPS status provided 1,253
references. The AI analysis left 292 articles. After title screening by two experts, 70 studies remained
for the title/abstract phase, and from these 46 articles passed to the full article appraisal.
None of the studies that reached the full article evaluation phase concerned the QPS yeast species
Candida cylindracea, Hanseniaspora uvarum, Komagataella pastoris, Komagataella phaffi,
Ogataea angusta, Saccharomyces bayanus, Saccharomyces pastorianus, Schizosac-
charomyces pombe, Xanthophyllomyces dendrorhous and Zygosaccharomyces rouxii.
Consequently, their QPS status does not change.
3.3.4.1. Debaryomyces hansenii
The anamorph name of D. hansenii is Candida famata.
A total of nine articles reached the final stage and were evaluated. For two of them, no safety
concerns were identified. Chen et al., 2019 performed a statistical study about the reported candidiasis
cases with patients with haematological malignancies and Hamzavi et al., 2019 described the presence
of D. hansenii in hospitalised persons although fungal infection had not been diagnosed. Seven reports
include safety concerns for humans; however, four of them had limitations in the species identification
(de Paula Menezes et al., 2018; Ali et al., 2019; Alobaid and Khan, 2019; Bignoumba et al., 2019).
Two of them presented retrospective studies (Taverna et al., 2019; Pandey et al., 2020) reporting
D. hansenii among fungal isolates from hospitalised patients with underlying disease/
immunosuppression. Finally, Ghazi et al. (2019) summarised epidemiological data regarding Candida
infections in the Mediterranean area, including the presence of D. hansenii. The article did not include
any new data, not evaluated in previous QPS evaluations.
In conclusion, the literature update did not identify any information that would change the QPS
status of D. hansenii.
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3.3.4.2. Kluyveromyces lactis
The anamorph name of K. lactis is Candida spherica.
One clinical study reached the full article evaluation phase (Bignoumba et al., 2019). However, the
paper had limitations in the methods for species identification. The literature update thus did not
identify any information that would change the QPS status.
3.3.4.3. Kluyveromyces marxianus
The anamorph name of K. marxianus is Candida kefyr.
A total of 11 studies reached the full article evaluation phase. Three of these had limitations in the
species identification (de Paula Menezes et al., 2018; Rodrigues et al., 2019; Prigitano et al., 2020).
One did not report a safety concern, since the hospitalised persons from which K. marxianus was
isolated had not been diagnosed with fungal infection (Hamzavi et al., 2019). Toth et al. (2019)
reported the response of clinical isolates of K. marxianus to a novel echinocandin, rezafungin. Five
retrospective studies of clinical isolate collections, often from specific hospitals, reported opportunistic
infections in immunocompromised patients, or nosocomial infections in hospitalised patients with
underlying disease (Hamzehee et al., 2019; Maheronnaghsh et al., 2019; Nemer et al., 2019; €Onal
et al., 2019; Pandey et al., 2020). The numbers of isolates confirmed as K. marxianus were low,
between one and three, corresponding to between < 1% and 8% of the total number of fungal
isolates obtained. Seth-Smith et al. (2019) reported bloodstream infection by K. marxianus in a male
patient diagnosed with acute myeloid leukaemia and undergoing chemotherapy. They hypothesised
that consumption of dairy products might have caused the infection, since the patient had regularly
consumed fermented dairy products and the single-nucleotide polymorphism phylogenetic analysis
including the 24 strains available in Genbank showed that the isolate was most similar to some dairy
strains of K. marxianus. However, it was not unequivocally shown that the infection was food-borne.
In conclusion, the literature update did not identify any information that would change the QPS
status of K. marxianus.
3.3.4.4. Cyberlindnera jadinii
The anamorph name of Cyberlindnera jadinii is Candida utilis. The previous official name of
Lindnera jadinii was changed to C. jadinii (Minter, 2009).
Four studies reached the full article evaluation phase. Three of these were clinical studies but had
limitations in the methods used for species identification (O’Reilly et al., 2019; Rodrigues et al., 2019;
Prigitano et al., 2020). Park et al. (2019) did not indicate safety concerns but showed that traditional
identification with biochemical growth tests may misidentify the opportunistic species Cyberlindnera/
Lindnera fabianii as L. jadinii. Thus, earlier clinical studies relying on growth tests might have
overestimated the occurrence of L. jadinii.
The literature update did not identify any information that would change the QPS status.
3.3.4.5. Saccharomyces cerevisiae
Four studies have reported safety concerns for humans. In three of them (Chakravarty et al., 2019;
Gupta et al., 2019; Lee and Jang, 2019), no information about the identification method is described.
Daliri et al. (2019) described information that has been described by other authors, that S. cerevisiae
(var boulardii), may in rare cases cause infection when administered as a probiotic to patients with
gastrointestinal diseases. Raghavan et al. (2019) provided a general review on S. cerevisiae with no
new relevant information in relation to QPS status.
In conclusion, the literature update did not identify any information that would change the QPS
status of S. cerevisiae.
3.3.4.6. Wickerhamomyces anomalus
The anamorph name of W. anomalus is Candida pelliculosa.
Five studies reached the full article evaluation phase. One clinical case study (Marwah et al., 2019)
could not be properly evaluated since it did not report the methods used for species identification. Three
retrospective studies (Liu et al., 2019; Xu et al., 2019; Pandey et al., 2020) reported W. anomalus among
fungal isolates from hospitalised patients with underlying disease/immunosuppression, with a prevalence
of 6–13% of the isolates. Park et al. (2019) showed that traditional species identification with biochemical
growth tests may misidentify the opportunistic species Cyberlindnera/Lindnera fabianii as W. anomalus.
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Thus, earlier clinical studies relying on morphological or growth test identification might have
overestimated the prevalence of W. anomalus.
The literature update did not identify any information that would change the QPS status.
3.3.4.7. Yarrowia lipolytica
The anamorph name of Y. lipolytica is Candida lipolytica.
Four studies reached the full article evaluation phase. One clinical (Bignoumba et al., 2019) and one
veterinary study (Tesfaye et al., 2019) had limitations regarding methods for species identification.
Zieniuk and Fabiszewska (2018) present a review and synthesis of the possible pathogenicity,
epidemiology and antifungal drugs susceptibility of this yeast that may be associated with opportunistic
infections. Finally, Liu et al. (2019) found in a retrospective study that one isolate (prevalence 3%)
from hospitalised patients with candidaemia was Y. lipolytica.
No new information was found that would change the QPS status of Y. lipolytica.
3.3.5. Viruses used for plant protection
3.3.5.1. Alphaflexiviridae
A search for papers potentially relevant for the QPS evaluation of viruses of the Alphaflexiviridae
and Potyviridae 14 provided 42 references. No paper dealing with Alphaflexiviridae reached the final
selection phase; thus, no new safety concern was found.
3.3.5.2. Potyviridae
No paper dealing with Potyviridae reached the final selection phase; thus, no new safety concern
was found.
3.3.5.3. Baculoviridae
A search for papers potentially relevant for the QPS evaluation of Baculoviridae provided 64
references. One article reached the final selection phase, but the full text was not in English. The ELS
did not reveal any information that would change the current QPS status of any of the above virus
families.
3.4. Taxonomic revision of the Lactobacillus genus for the QPS
assessment and the QPS list
The genus Lactobacillus has been recently divided into 25 new genera, based on phylogenetic,
phenotypical and habitat differences shown by its 261 member species, while their species names are
retained (Zheng et al., 2020). As a consequence, the 37 species that are considered as QPS became
classified into 13 genera, of which 10 species are now included in the new genus Lactobacillus (homonym
to the previous genus appellation), five belong to the genus Limosilactobacillus, four to Lentilactobacillus,
three to each of Ligilactobacillus, Lacticaseibacillus and Lactiplantibacillus, two to Companilactobacillus
and Latilactobacillus and one to each of the genera Levilactobacillus, Secundilactobacillus,
Loigolactobacillus, Fructilactobacillus and Lapidilactobacillus. In the following table, the previous and new
designations of the QPS species are presented, following the alphabetical order of their specific names.
‘Classical’ denomination ‘Updated’ denomination
Lactobacillus acidophilus Lactobacillus acidophilus
Lactobacillus alimentarius Companilactobacillus alimentarius
Lactobacillus amylolyticus Lactobacillus amylolyticus
Lactobacillus amylovorus Lactobacillus amylovorous
Lactobacillus animalis Ligilactobacillus animalis
Lactobacillus aviarius Ligilactobacillus aviarius
Lactobacillus brevis Levilactobacillus brevis
Lactobacillus buchneri Lentilactobacillus buchneri
Lactobacillus casei Lacticaseibacillus casei
Lactobacillus collinoides Secundilactobacillus collinoides
Lactobacillus coryniformis Loigolactobacillus coryniformis
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‘Classical’ denomination ‘Updated’ denomination
Lactobacillus crispatus Lactobacillus crispatus
Lactobacillus curvatus Latilactobacillus curvatus
Lactobacillus delbrueckii Lactobacillus delbrueckii
Lactobacillus dextrinicus Lapidilactobacillus dextrinicus
Lactobacillus diolivorans Lentilactobacillus dioliovorans
Lactobacillus farciminis Companilactobacillus farciminis
Lactobacillus fermentum Limosilactobacillus fermentum
Lactobacillus gallinarum Lactobacillus gallinarum
Lactobacillus gasseri Lactobacillus gasseri
Lactobacillus helveticus Lactobacillus helveticus
Lactobacillus hilgardii Lentilactobacillus hilgardii
Lactobacillus johnsonii Lactobacillus johnsonii
Lactobacillus kefiranofaciens Lactobacillus kefiranofaciens
Lactobacillus kefiri Lentilactobacillus kefiri
Lactobacillus mucosae Limosilactobacillus mucosae
Lactobacillus panis Limosilactobacillus panis
Lactobacillus paracasei Lacticaseibacillus paracasei
Lactobacillus paraplantarum Lactiplantibacillus paraplantarum
Lactobacillus pentosus Lactiplantibacillus pentosus
Lactobacillus plantarum Lactiplantibacillus plantarum
Lactobacillus pontis Limosilactobacillus pontis
Lactobacillus reuteri Limosilactobacillus reuteri
Lactobacillus rhamnosus Lacticaseibacillus rhamnosus
Lactobacillus sakei Latilactobacillus sakei
Lactobacillus salivarius Ligilactobacillus salivarius
Lactobacillus sanfranciscensis Fructilactobacillus sanfranciscensis
To maintain continuity within the QPS list, all the strains belonging to a previous designed
Lactobacillus species will be transferred to the new species. Both the previous and new names will be
retained.
4. Conclusions
ToR 1: Keep updated the list of biological agents being notified, in the context of a technical dossier
to EFSA Units (such as Feed, Food Ingredients and Packaging, Nutrition, Pesticides, Genetically
Modified Microorganisms), for intentional use in feed and/or food or as sources of food and feed
additives, enzymes, plant protection products for safety assessment:
• Between October 2019 and March 2020, the QPS list was updated with 39 notifications that
were received by EFSA, of which 26 were for feed additives, two for food enzymes and food
additives, five for novel foods, five for plant protection products and one for genetically
modified organisms.
ToR 2: Review taxonomic units previously recommended for the QPS list and their qualifications
when new information has become available:
• In relation to the results of the monitoring of possible new safety concerns related to the QPS
list, there were no results that justify removal of any TUs from the QPS list or changes in their
respective qualifications.
ToR 3: (Re)assess the suitability of taxonomic units notified to EFSA not present in the current QPS
list for their inclusion in that list:
• Of the 39 notifications received, 19 were related to TUs that already had QPS status and did
not require further evaluation.
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• Of the remaining 20 notifications, 14 were related to TUs excluded from QPS evaluation: five
were notifications of filamentous fungi, five of Escherichia coli, two of Enterococcus faecium,
two of Streptomyces spp. (one Streptomyces aureofaciens and one Streptomyces lasaliensis).
• Six notifications, corresponding to six TUs, were evaluated for possible QPS status, two of
these (Akkermansia muciniphila and Galdieria sulphuraria) for the first time. Clostridium
butyricum, Corynebacterium ammoniagenes, Pseudomonas chlororaphis and Komagataella
pastoris were re-assessed because the recent notifications related to a different intended use
or because an update was requested in relation to the new mandate.
○ Akkermansia muciniphila is not recommended for QPS status due to safety concerns;
○ Galdieria sulphuraria is not recommended for QPS status due to a lack of body of
knowledge regarding its use in the food and feed chain;
○ C. butyricum is not recommended for QPS status because some strains contain
pathogenicity factors; this species is excluded for further QPS evaluation;
○ P. chlororaphis is not recommended for QPS status due to a lack of body of knowledge;
○ The QPS status with the qualification ‘for production purposes only’ of C. ammoniagenes is
confirmed;
○ The QPS status with the qualification ‘for enzyme production’ of K. pastoris is confirmed.
• The genus Lactobacillus has been recently divided into 25 new genera. As a consequence, the
37 species that are considered as QPS were reclassified into 13 genera. To maintain continuity
within the QPS list, all the strains belonging to a previous designed Lactobacillus species will be
transferred to the new species. The previous and new names will both be retained.
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Glossary
Anamorph name Valid name of a fungus based on the asexual reproductive state
(morphologically)
Antimicrobial compounds Antibiotics, bacteriocins and/or small peptides with antimicrobial
activity
Basonym name The earliest validly published name of a Staxon
Have the same type (specimen) and the same taxonomic rank
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Synonymous name/Homotypic
synonym





BIOHAZ EFSA Panel on Biological Hazards
ELS extensive Literature Search
FEEDAP EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP)
FIP EFSA Food ingredients and packaging Unit
FSTA Food Science Technology Abstracts
GMM genetically modified microorganism
IJSEM International Journal of Systematic and Evolutionary Microbiology
NOAEL no observed adverse effect level
QPS qualified presumption of safety
PPP plant protection product
SCP single cell protein
ToR Terms of Reference
TU taxonomic unit
WG Working Group
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Appendix A – Search strategy followed for the (re)assessment of the
suitability of TUs notified to EFSA not present in the current QPS list for
their inclusion in the updated list (reply to ToR 3)
A.1. Clostridium butyricum
PubMed; Clostridium butyricum AND toxi*: 40 hits
A.2. Corynebacterium ammoniagenes
A search was conducted using the taxonomic unit name for the last 5 years in WoS (core
collection). The time frame of the literature search was restricted because this TU was re-assessed
during this mandate. A total of 24 references were found and they were all screened.
A.3. Pseudomonas chlororaphis
PubMed; Pseudomonas chlororaphis: 365 hits.
A.4. Komagataella pastoris
A search was conducted including the last 10 years and it provided 142 references in PubMed with
Komagataella pastoris and Pichia pastoris. The time frame of the literature search was restricted
because this TU was re-assessed during this mandate.
A.5. Galdieria sulphuraria
PubMed; Galdieria sulphuraria: 86 hits; all screened.
A.6. Akkermansia muciniphila
Akkermansia muciniphila, (present in title), 160 hits.
Akkermansia muciniphila and pathogenic, 36 hits.
PubMed and Web of Science core collection.
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Appendix B – Protocol for Extensive literature search (ELS), relevance
screening and article evaluation for the maintenance and update of list of
QPS-recommended biological agents (reply to ToR 2)
The protocol for extensive literature search (ELS) used in the context of the EFSA mandate on the
list of QPS-recommended biological agents intentionally added to the food or feed (EFSA-Q-2020-
00077) is available on the EFSA Knowledge Junction community on Zenodo, at: https://doi.org/10.
5281/zenodo.3607190
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Appendix C – Search strategies for the maintenance and update of list of
QPS-recommended biological agents (reply to ToR 2)
The search strategies for each taxonomic unit (TU), i.e. the string for each TU and the search
outcome, are available on the EFSA Knowledge Junction community on Zenodo at: https://doi.org/10.
5281/zenodo.3607193
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Appendix D – References selected from the ELS exercise as relevant for
the QPS for searches from July to December 2019 (reply to ToR 2)
Gram-Positive Non-Sporulating Bacteria
Bifidobacterium
Pruccoli G, Silvestro E, Pace Napoleone C, Aidala E, Garazzino S and Scolfaro C, 2019. Are







Ajam M, Adam O, Yeddi A, Kahlid M, Shokr M and Afonso L, 2019. Prosthetic aortic valve endocarditis
in a patient with birt-hogg-dube syndrome due to Lactobacillus Paracasei. Cardiology Research, 10,
245–248. https://doi.org/10.14740/cr901
Cavicchiolo ME, Magnani M, Calgaro S, Bonadies L, Castagliulo I, Morelli L, Verlato G and Baraldi E,
2019. Neonatal Sepsis associated with lactobacillus supplementation. Journal of Perinatary Medicine,
48, 87–88. https://doi.org/10.1515/jpm-2019-0268
Yelin I, Flett KB, Merakou C, Mehrotra P, Stam J, Snesrud E, Hinkle M, Lesho E, McGann P, McAdam AJ,
Sandora TJ, Kishony R and Priebe GP, 2019. Genomic and epidemiological evidence of bacterial


















Al-Tulaibawi N, 2019. Prevalence and sensitivity of bacterial urinary tract infection among adult diabetic
patients in misan province, Iraq. Journal of Pure and Applied Microbiology, 13, 847–853. https://doi.
org/10.22207/jpam.13.2.20
Nadaș GC, Filipoi CD, Bouari CM, Buzura-Matei IA, Chirila F, Novac CS and Fiț NI, 2019. The
identification and antimicrobial susceptibility profile of conjunctival flora from dogs. Lucrari Stiintifice
- Universitatea de Stiinte Agricole a Banatului Timisoara, Medicina Veterinara 52, 78–81.
BIOHAZ statement on QPS: suitability of taxonomic units notified until March 2020
www.efsa.europa.eu/efsajournal 33 EFSA Journal 2020;18(7):6174
Thanganadar Appapalam S, Muniyan A, Vasanthi Mohan K and Panchamoorthy R, 2019. A study on
isolation, characterization, and exploration of multiantibiotic-resistant bacteria in the wound site of












Ali R, Hameed ZH, Hussain AF and Hamu A, 2019. Evaluation effectiveness of fluconazole and mirabilis
jalapa extract against some pathological fungi. Biochemistry Cellular Archives, 19, 2467–2473.
https://doi.org/10.35124/bca.2019.19.s1.2467
Alobaid K and Khan Z, 2019. Epidemiologic characteristics of adult candidemic patients in a secondary
hospital in kuwait: a retrospective study. Journal of Mycology Medicine, 29, 35–38. https://doi.org/
10.1016/j.mycmed.2018.12.001
Bignoumba M, Onanga R, Bivigou Mboumba B, Gafou A, Mouanga Ndzime Y, Lendamba RW, Mbombe
Moghoa K and Kassa Kassa RF, 2019. Vulvovaginal Candidiasis among symptomatic women of
childbearing age attended at a medical analysis laboratory in franceville, Gabon. Journal of
Mycology Medicine, 29, 317–319. https://doi.org/10.1016/j.mycmed.2019.100895
Chakravarty S, Parashar A and Acharyya S, 2019. Saccharomyces cerevisiae sepsis following probiotic
therapy in an infant. Indian Pediatrics, 56, 971–972. https://doi.org/10.1007/s13312-019-1655-7
Chen CY, Cheng A, Tien FM, Lee PC, Tien HF, Sheng WH and Chen YC, 2019. Chronic disseminated
candidiasis manifesting as hepatosplenic abscesses among patients with hematological
malignancies. BMC Infectious Diseases, 19, 635. https://doi.org/10.1186/s12879-019-4260-4
Daliri EBM, Lee BH and Oh DH, 2019. “Chapter 35 - Safety of Probiotics in Health and Disease.” In The
Role of Functional Food Security in Global Health, edited by Ram B. Singh, Ronald Ross Watson,
and Toru Takahashi, 603–622: Academic Press.
de Paula Menezes R, Silva FF, Melo SGO, Alves PGV, Brito MO, de Souza Bessa MA, Amante Penatti MP,
Pedroso RS, Abdallah VOS and Roder D, 2018. Characterization of Candida Species Isolated from
the Hands of the Healthcare Workers in the Neonatal Intensive Care Unit. Medicine Mycology.
https://doi.org/10.1093/mmy/myy101
Ghazi S, Rafei R, Osman M, El Safadi D, Mallat H, Papon N, Dabboussi F, Bouchara JP and Hamze M,
2019. The epidemiology of candida species in the middle east and North Africa. Journal of Mycology
Medicine, 29, 245–252. https://doi.org/10.1016/j.mycmed.2019.07.006
Gupta P, Singh YP and Taneja A, 2019. Saccharomyces: a friend or foe in icu (a case report with
solution). Indian Journal of Critical Care Medicine, 23, 430–431. https://doi.org/10.5005/jp-journals-
10071-23239
Hamzavi SS, Amanati A, Badiee P, Kadivar MR, Jafarian H, Ghasemi F, Haghpanah S, Dehghani M and
Norouzian Baghani A, 2019. Changing face of Candida Colonization pattern in pediatric patients
with hematological malignancy during repeated hospitalizations, results of a prospective
observational study (2016–2017) in Shiraz, Iran. BMC Infectious Diseases, 19, 759. https://doi.org/
10.1186/s12879-019-4372-x
Hamzehee S, Kalantar-Neyestanaki D, Kuchak Afshari SA and Ayatollahi Mousavi SA, 2019. Molecular
identification of Candida species, assessment of the antifungal susceptibility and the genetic
relationship of Candida albicans isolated from immunocompromised patients in Kerman, Iran. Gene
Reports, 17. https://doi.org/10.1016/j.genrep.2019.100484
BIOHAZ statement on QPS: suitability of taxonomic units notified until March 2020
www.efsa.europa.eu/efsajournal 34 EFSA Journal 2020;18(7):6174
Lee HM and Jang PS, 2019. A case of Saccharomyces cerevisiae fungemia in a premature infant
treated with probiotics. European Journal of Pediatrics, 178, 1741. https://doi.org/10.1007/s00431-
019-03466-w
Liu WL, Lai CC, Li MC, Wu CJ, Ko WC, Hung YL, Tang HJ and Hsueh PR, 2019. Clinical manifestations
of candidemia caused by uncommon candida species and antifungal susceptibility of the isolates in
a regional hospital in Taiwan, 2007-2014. Journal of Microbiolial Immunology Infection, 52, 612–
619. https://doi.org/10.1016/j.jmii.2017.08.007
Maheronnaghsh M, Dehghan P, Fatahinia M and Rezaei-Matehkolaei A, 2019. In vitro activity of new
azole luliconazole compared to fluconazole against candida strains isolated from oral lesions of
cancer patients. Journal of Research in Medical and Dental Science, 7, 132–138.
Marwah P, Kumar S and Marwah A, 2019. Pichia anomala, a rare cause of nosocomial fungal sepsis in
newborn. Is empirical use of third generation cephalosporin to blame? Journal of Clinical and
Diagnostic Research. https://doi.org/10.7860/jcdr/2019/39543.12956.
Nemer S, Imtiaz T, Varikkara M, Collier A and Bal AM, 2019. Management of candidaemia with
reference to the european confederation of medical mycology quality indicators. Infectious Diseases
(London), 51, 527–533. https://doi.org/10.1080/23744235.2019.1606436
€Onal U, Metin DY, Karaca C, Polat SH, Ersin and Tasbakan MI, 2019. Retrospective evaluation of
candidemic patients among general surgery department in a tertiary care university hospital.
Turkish Journal of Surgery, 35, 210–213. https://doi.org/10.5578/t
O’Reilly MA, Govender D, Kirkwood AA, Vora A, Samarasinghe S, Khwaja A, Grandage V, Rao A, Ancliff
P, Pavasovic V, Cheng D, Carpenter B, Daw S, Hough R and O’Connor D, 2019. The incidence of
invasive fungal infections in children, adolescents and young adults with acute lymphoblastic
leukaemia/lymphoma treated with the Ukall 2011 Protocol: A Multicentre Retrospective Study.
British Journal of Haematology, 186, 327–329. https://doi.org/10.1111/bjh.15798
Pandey N, Gupta MK, Paul P and Tilak R, 2020. Necessity to identify candida species accurately with
minimum inhibitory concentration determination in each case of bloodstream infections. Journal of
Infectious Public Health, 13, 753–758. https://doi.org/10.1016/j.jiph.
Park JH, Oh J, Sang H, Shrestha B, Lee Hs, Koo J, Cho SI, Choi JS, Lee MH, Kim J and Sung GH, 2019.
Identification and antifungal susceptibility profiles of Cyberlindnera Fabianii in Korea. Mycobiology,
47, 449–456. https://doi.org/10.1080/12298093.2019.16
Prigitano A, Cavanna C, Passera M, Gelmi M, Sala E, Ossi C, Grancini A, Calabro M, Bramati S, Tejada
M, Lallitto F, Farina C, Rognoni V, Fasano MA, Pini B, Romano L, Cogliati M, Esposto MC and
Tortorano AM, 2020. Evolution of Fungemia in an Italian Region. Journal of Mycology Medicine, 30,
100906. https://doi.org/10.1016/j.mycmed.2019.100906
Raghavan V, Aquadro CF and Alani E, 2019. Baker’s yeast clinical isolates provide a model for how
pathogenic yeasts adapt to stress. Trends Genetics, 35, 804–817. https://doi.org/10.1016/j.tig.
2019.08.002
Rodrigues LS, Motta FA, Picharski GL, Vasconcelos TM, Riccieri MC and Dalla-Costa LM, 2019. Invasive
Candidiasis: risk factor for mortality in a pediatric tertiary care hospital in South of Brazil. Medicine
(Baltimore), 98, e15933. https://doi.org/10.1097/md.0000000000015933journal
Seth-Smith HMB, Buchler AC, Hinic V, Medinger M, Widmer AF and Egli A, 2020. Bloodstream infection
with candida kefyr/kluyveromyces marxianus: case report and draft genome. Clinical Microbiology
Infectious, 26, 522–524. https://doi.org/10.1016/j.cmi.2019.11.014
Taverna CG, Cordoba S, Vivot M, Szusz W, Vivot W, Bosco-Borgeat ME and Davel G, 2019.
Reidentification and Antifungal Susceptibility Profile of Candida Guilliermondii and Candida Famata
Clinical Isolates from a Culture Collection in Argentina. Medicine Mycology, 57, 314–323. https://doi.
org/10.1093/mmy/myy038
Tesfaye B, Matios L, Getachew T, Tafesse K, Abebe O, Letebrihan Y, Mekdes T and Tilaye D, 2019.
Study on bovine mastitis with isolation of bacterial and fungal causal agents and assessing
antimicrobial resistance patterns of isolated staphylococcus species in and around sebeta Town,
Ethiopia. African Journal of Microbiology Research, 13 23–32. https://doi.org/10.5897/ajmr2018.
8909
Toth Z, Forgacs L, Locke JB, Kardos G, Nagy F, Kovacs R, Szekely A, Borman AM and Majoros L, 2019.
In vitro activity of rezafungin against common and rare candida species and Saccharomyces
cerevisiae. Journal of Antimicrobial Chemotherapy, 74, 3505–3510. Accessed 5/18/2020. https://doi.
org/10.1093/jac/dkz390
BIOHAZ statement on QPS: suitability of taxonomic units notified until March 2020
www.efsa.europa.eu/efsajournal 35 EFSA Journal 2020;18(7):6174
Xu H, Yu SY, Zhou ML, Ning YT, Xiao M, Li XG, Chen M, Kong F, Chen S, Ming L and Xu YC, 2019.
Epidemiology and antifungal susceptibility patterns of invasive fungal infections from 2012 to 2014
in a teaching hospital in central China. Infectious Drug Resistance, 12, 3641–3651. https://doi.org/
10.2147/idr.s227839
Zieniuk B and Fabiszewska A, 2018. Yarrowia Lipolytica: a beneficious yeast in biotechnology as a rare
opportunistic fungal pathogen: a minireview. World Journal of Microbiolial Biotechnology, 35, 10.
https://doi.org/10.1007/s11274-018-2583-8







BIOHAZ statement on QPS: suitability of taxonomic units notified until March 2020
www.efsa.europa.eu/efsajournal 36 EFSA Journal 2020;18(7):6174
Appendix E – The 2020 updated list of QPS Status recommended biological
agents in support of EFSA risk assessments
The list of QPS status recommended biological agents (EFSA BIOHAZ Panel, 2020a,b) is being
maintained in accordance with the mandate of the BIOHAZ Panel (2020–2022), extended for the
following years. Possible additions to this list are included around every 6 months, with the latest
Panel Statement adopted in December 2019. These additions are published as updates to the Scientific
Opinion (EFSA BIOHAZ Panel, 2020a,b); the updated QPS list is available at https://doi.org/10.2903/
j.efsa.2020.5966 and, as of January 2018, also as supporting information linked to every
Panel Statement available on the Knowledge Junction at https://doi.org/10.5281/zenodo.1146566
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EFSA-Q-2019-00736 Y No (already QPS)






EFSA-Q-2019-00602 Y No (already QPS)




EFSA-Q-2019-00736 Y No (already QPS)
Bacillus subtilis ABS747 Feed additives Zootechnical
additives
Gut flora stabiliser EFSA-Q-2019-00803 Y No (already QPS)




Digestibility enhancer EFSA-Q-2020-00004 Y No (already QPS)
Bacillus subtilis ABS1781 Feed additives Zootechnical
additives





Vitamin EFSA-Q-2020-00160 Y No (already QPS)












Y No (already QPS)
www.efsa.europa.eu/efsajournal 38 EFSA Journal 2020;18(7):6174































Y No (already QPS)












Y No (already QPS)






EFSA-Q-2019-00603 Y No (already QPS)
Clostridium butyricum FERM BP-2789 Feed additives Zootechnical
additives
Gut flora stabilisers EFSA-Q-2019-00802 N Yes
Corynebacterium
ammoniagenes













CG MCC 7.358 Feed additives Nutritional
additives
Production of L-Valine EFSA-Q-2019-00788 Y No (already QPS)
Corynebacterium
glutamicum




EFSA-Q-2020-00007 Y No (already QPS)
Corynebacterium
glutamicum
KCCM 80187 Feed additives Sensory additives Flavouring compound EFSA-Q-2020-00155 Y No (already QPS)
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Amino acid EFSA-Q-2020-00134 Y No (already QPS)






strain DSM 7134) is an
additive already
authorised
EFSA-Q-2019-00741 N No (excluded)
Enterococcus faecium DSM 7134 Feed additives Zootechnical
additives
Functional group: b EFSA-Q-2019-00156 N No (excluded)







EFSA-Q-2020-00008 N No (excluded)




















Escherichia coli GMO Novel foods Novel Food Processing aid in the
production of 3-
fucosyllactose
EFSA-Q-2019-00666 N No (excluded)
Escherichia coli BL21 (DE3) Novel foods Enzyme production Production of D-
tagatose-3-epimerase
(dt3) used for the
production of allulose
EFSA-Q-2020-00141 N No (excluded)
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strain C735.15 Feed additives Coccidiostats and
histomonostats









EFSA-Q-2019-00745 N No (excluded)
Filamentous Fungi








EFSA-Q-2019-00639 N No (excluded)
Antrodia camphorata Novel foods Freeze-dried
mycelia
The novel food consists
of freeze-dried mycelia
to be used as a food
supplement
EFSA-Q-2019-00759 N No (excluded)




Fungicide EFSA-Q-2019-00113 N No (excluded)
















EFSA-Q-2019-00697 N No (excluded)
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As active material in
food contact material,
as oxygen scavenger
(for wine bottles and
bag-in-box)
EFSA-Q-2019-00588 Y No (already QPS)
Saccharomyces
cerevisiae




EFSA-Q-2019-00740 Y No (already QPS)




Komagataella phaffii (CECT 13171) Feed additives Zootechnical
additives
Functional group: a, c EFSA-Q-2020-00161 Y No (already QPS)
(a): To find more details on specific applications please access the EFSA website – Register of Questions: http://registerofquestions.efsa.europa.eu/roqFrontend/ListOfQuestionsNoLogin?0&panel=
ALL
(b): Where no link is given, this means that the risk assessment has not yet been published.
(c): Included in the QPS list as adopted in December 2019 (EFSA BIOHAZ Panel, 2020b) and respective updates which include new additions (latest: EFSA BIOHAZ Panel, 2020a).
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